Corona Remedies has received Good Manufacturing Practice (GMP) compliance certification from the Brazilian Health Regulatory Agency, ANVISA. This approval covers the company's oral solid dosage (OSD) and hormone manufacturing facilities located at Bhayla, Ahmedabad.

The certification marks a significant regulatory milestone for the pharmaceutical manufacturer. By securing compliance from ANVISA, the company strengthens its position for exporting medical products to the Brazilian market, one of the largest healthcare markets in Latin America.

Regulatory Details

The disclosure was made to the BSE Limited and National Stock Exchange of India Limited on October 22, 2026. The company cited Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as the basis for this intimation.

Facilities Certified

The GMP certification applies specifically to two distinct manufacturing units within the Ahmedabad complex:

• Oral Solid Dosage (OSD) facility
• Hormone manufacturing facility

Both facilities are situated at Bhayla, Ahmedabad. The certification ensures that these units meet the stringent quality standards required by Brazilian health authorities for drug importation and sale.

Sepia Investments Limited, Sage Investment Trust, and Anchor Partners disposed of a combined 26,29,880 equity shares of Corona Remedies Limited through open market sales on the National Stock Exchange of India Limited (NSE).

The transaction, executed on September 10, 2026, was disclosed under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 (SAST). The sellers are persons acting in concert. The formal disclosure letter was dated September 18, 2026, and signed by Panir Pushpom Soobiah for Sepia Investments Limited, and Ashley Menezes for both Sage Investment Trust and Anchor Partners.

Disposal Breakdown

Sepia Investments Limited led the exit, offloading 24,85,476 shares, representing 4.06% of the total voting capital. Sage Investment Trust sold 51,641 shares (0.08%), while Anchor Partners disposed of 92,763 shares (0.15%).

Post-Transaction Holdings

Following the sale, Sepia Investments’ holding fell from 12.68% to 8.62%. Sage Investment Trust’s stake reduced from 0.26% to 0.18%, and Anchor Partners’ holding declined from 0.47% to 0.32%.

Corona Remedies Limited has an equity share capital of ₹61,16,00,880, divided into 61,16,008 equity shares of face value ₹10 each. The total diluted share capital remains unchanged at this level.